GlassScriptPhysician profile
Douglas B Moericke
NPI 1366446841
$1,107.58
in general payments reported to CMS, 2019-2025
15 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.40 · 2022: $258 · 2023: $296 · 2024: $262 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $345.90 | 2023-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $294.05 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $161.71 | 2021-2024 | Xarelto |
| Abbvie INC. | $69.19 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $32.60 | 2024 | Gvoke Hypopen |
| Vertex Pharmaceuticals Incorporated | $31.23 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.45 | 2023 | Lifevest |
| Alkermes, INC. | $22.82 | 2024 | Vivitrol |
| Ultragenyx Pharmaceutical INC. | $21.22 | 2021 | |
| Corcept Therapeutics | $20.07 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.23 | 2025 | Jardiance |
| Mylan Specialty L.P. | $18.86 | 2024 | Yupelri |
| Pfizer INC. | $17.34 | 2021 | |
| Lilly USA, LLC | $15.58 | 2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Moericke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.